Short-acting GLP-1RAs (exenatide [ t 1/2 of 2.4 hours] and lixisenatide [ t 1/2 of 24 hours] administered before meals twice-daily and once-daily, respectively) exhibit intermittent GLP-1 receptor activation translating into potent deceleration of upper gastrointestinal motility, an effect which is sustained during prolonged treatment
Most of what shows up in trial data is gastrointestinal and most of it is tied to dose escalation rather than long term stable use, which is an important distinction most people dont know going in
Tirzepatide, for instance, stands out by targeting not only the GLP-1 receptor but also the glucose-dependent insulinotropic polypeptide (GIP) receptor, offering a dual mechanism of action
hs-CRP: A measure of systemic inflammation in the body
Pleiotropic effects of GLP-1 and analogs on cell signaling, metabolism, and function
They have this special system that pumps this special aromatherapy orange scent into the air that smells so good